Detailed data from Novo Nordisk’s comparative Devote study confirms that the company’s new insulin is as safe as and markedly more effective than its rival, the top-selling Lantus from Sanofi. This information can strengthen Novo’s position in the important ongoing negotiations with US payers.
BY MARTIN HAVTORN PETERSEN Offentliggjort 14.06.17 kl. 20:34
Log ind for at læse artikler
Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.
The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.
Denmark’s ALK is ready to go “full steam” in the launch of a promising tablet against house dust mite allergy on the US market as early as this year. The only obstacle is a formal handover of the marketing permit from former partner Merck, which could push the launch into 2018.
Genmab’s Darzalex royalties now cover the company’s operating costs and in addition to that, the cancer drug continues its expansion to new markets. And according to CEO, Jan van de Winkel, Genmab could potentially raise its guidance this year.
Zealand Pharma has listed on the Nasdaq Global Select Market in addition to its listing in Copenhagen, raising USD 89 in the process. But the move does not mean the biotech company has lost faith in the Danish investor base, says CEO Britt Meelby Jensen.
Der har været godt gang i Coloplasts kinesiske forretning i tredje kvartal, hvor året ellers startede med negativ vækst i selskabets sårplejedivision. Den positive udvikling fortsætter ind i fjerde kvartal, vurderer selskabets finansdirektør Anders Lonning-Skovgaard.